NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
14 trialsNCT04020809 2026-03-09
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04356729 2025-06-29
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed
NCT05483400 2025-03-30
TIRACAN
University Medical Center Groningen
Phase 2 Recruiting
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT05060003 2024-02-20
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Washington University School of Medicine
Phase 2 Terminated
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT03050060 2022-06-22
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Phase 2 Terminated
NCT02303951 2021-02-03
NEO-VC
University Hospital Tuebingen
Phase 2 Terminated